ClinicalTrials.gg
CompletedNCT03450876Updated Sep 11, 2020

Long Term Quality of Life in Melanoma Patients in Netherlands

An observational study in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
89
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.

Enrollment
27th of 32
89 · median 366
Started
2016
with 11 others
Observational
32 of 111
none open now
Registered
83rd of 111
by date

Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 27th largest by enrollment of the 32 observational ones that give a count, is one of 12 that started in 2016, is one of 32 observational ones, and was the 83rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Melanoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with advanced melanoma who survived at least 2 years and were treated with ipilimumab between 2011 and 2015 in one of the specified melanoma centers in the Netherlands.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient population: Adults ≥ 18 years of age at diagnosis, diagnosed with confirmed advanced (stage IV or unresectable stage III) melanoma, who have received at least one course of ipilimumab treatment (first, second, or second plus line; routine practice or study treatment) in one of the specified treatment centers, and who have survived at least 2 years after (completion of) ipilimumab treatment (measured from last ipilimumab administration)
  • Matched healthy control population: Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort

Exclusion criteria

Exclusion Criteria

  • Insufficient understanding of the Dutch language
  • Other anticancer treatment after ipilimumab or during study entry
  • Disease recurrence during the study

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
89 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy Control

    Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort

    Other: Non-Interventional

  • 24 to < 36 months post-ipilimumab treatment

    24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands

    Other: Non-Interventional

  • ≥ 36 to < 48 months post-ipilimumab treatment

    36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands

    Other: Non-Interventional

  • ≥ 48 months post-ipilimumab treatment

    Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    Non-Interventional

This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ C30)

    EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).

    Time frame: Baseline up to 3 years

Secondary outcomes

  1. Hospital Anxiety and Depression Scale (HADS)

    14-item questionnaire assesses symptoms of mood disturbance, yielding separate scale scores for anxiety and depression, as well as a total score

    Time frame: Baseline up to 3 years

  2. Multidimensional Fatigue Inventory (MFI)

    Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI)

    Time frame: Baseline up to 3 years

  3. Cancer Worry Scale (CWS)

    8-item questionnaire will be used to assess the prevalence of cancer-specific distress in melanoma survivors and in healthy controls

    Time frame: Baseline up to 3 years

  4. European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health

    Sexual health will be assessed with the European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health

    Time frame: Baseline up to 3 years

  5. Functional Assessment of Cancer Therapy-Melanoma questionnaire (FACT-M)

    51-item measurement of quality of life

    Time frame: Baseline up to 3 years

  6. EuroQOL-5D (EQ-5D) survivors

    Generic health status will be assessed with the EuroQOL-5D (EQ-5D) survivors

    Time frame: Baseline up to 3 years

  7. Impact of Cancer Questionnaire (IOCv2)

    81 items that present statements regarding specific impacts of cancer to which respondents indicate their level of agreement from 1 (strongly disagree) to 5 (strongly agree). Seventy items apply to all survivors, 3 to currently employed respondents, 4 to respondents not currently partnered, and 4 to currently partnered respondents

    Time frame: Baseline up to 3 years

  8. Work Ability Index questionnaire (WAI)

    13-item questionnaire developed to obtain survivors' experiences with return to work and work performance

    Time frame: Baseline up to 3 years

  9. EORTC information module (EORTC QLQINFO25)

    Information needs will be assessed with the EORTC information module (EORTC QLQINFO25)

    Time frame: Baseline up to 3 years

07

Study locations

1 site
  • Local Institution
    Amsterdam, 1066 CX, Netherlands
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jun 2020, 42 months.

Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's 42 months is close to that.

Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2018
First posted
Mar 1, 2018
StartActual
Dec 15, 2016
Primary completionActual
Jun 17, 2020
CompletionActual
Jun 17, 2020
Last update
Sep 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03450876
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Dec 15, 2016
Primary completion
Jun 17, 2020
Completion
Jun 17, 2020
Last update
Sep 11, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion